TRANSCRIPTIONAL PROFILE OF CANCER-TESTICULAR ANTIGENS IN PATIENTS WITH BREAST CANCER
https://doi.org/10.15789/1563-0625-2018-3-383-390
Abstract
To identify new effective targets for immunotherapy of breast cancer, based on cancer-testis antigens (CTA), the associations were studied between CTA gene expression, clinical and pathological characteristics of breast cancer. Therefore, the aim of the study was to perform screening of CTAs specific to breast tissue tumors (luminal types A and B) based on assessment of the transcriptional profile of cancer-testis genes in the patients of different ages. To evaluate these relations, paired surgical biopsies (normal and tumor) of breast tissue of 32 patients (64 samples) aged 38-86 years were used. Relative expression of 16 genetic loci (MAGEA1, MAGEA2, MAGEA3, MAGEA4, MAGEB1, MAGEB2, GAGE1, GAGE3, GAGE4, MAGEC1, BAGE, XAGE3, NY-ESO1, SSX2, SYCP1 and PRAME1) was determined by the RT-qPCR. It was found that the transcriptional profile of CTA differs in different age groups of patients (at the age of < 55 years, overexpression of MAGEA3 was noted; after 55 years, MAGEA1, MAGEB1, BAGE, NY-ESO1, GAGE1 and GAGE3 were more expressed). In the luminal type A cancer, overexpression of MAGEA1, MAGEA2, MAGEA4, MAGEB1, MAGEB2, GAGE3, GAGE4, MAGEC1 and PRAME1, whereas in B type cancer, the genes with increased expression were not detected. These differences should be considered when planning immunotherapy, can be used as biomarkers for both breast cancer as clinical entity, and, in particular, for its individual subtypes.
About the Authors
D. I. Vodolazhskiy
Rostov Research Institute of Oncology
Russian Federation
Russian Federation
PhD (Biology), Head, Laboratory of Molecular Oncology.
Rostov-on-Don
D. S. Kutilin
Rostov Research Institute of Oncology
Russian Federation
Russian Federation
Kutilin Denis S. - PhD (Biology), Senior Research Associate, Laboratory of Molecular Oncology.
344037, Rostov-on-Don, 14th Line, 63, bldg 8, phone: 7 (863) 300-02-00 (add. 472)
Kh. A. Mogushkova
Rostov Research Institute of Oncology
Russian Federation
Russian Federation
Research Fellow.
Rostov-on-Don
O. I. Kit
Rostov Research Institute of Oncology
Russian Federation
Russian Federation
PhD, MD (Medicine), Professor, General Director.
Rostov-on-Don
References
1. Vodolazhskiy D.I., Kutilin D.S., Mogushkova Kh.A., Vashchenko L.N., Nikitina V.P., Kit O.I. Transcriptional activity of cancer-testis antigens in patients with breast cancer of luminal subtypes A and B. Sovremennye problemy nauki i obrazovaniya = Modern Problems of Science and Education, 2017, no. 4. (In Russ.)
2. Kaprin A.D., Starinskiy V.V., Petrova G.V. Status of cancer care for the population of Russia in 2013. Moscow: MNIOI them. P.A. Herzen, Ministry of Health and Social Development of Russia, 2014. 236 p.
3. Kutilin D.S., Dimitriadi S.N., Vodolazhsky D.I., Frantsiyants E.M., Kit O.I. Effect of thermal ischemia-reperfusion on expression of apoptosis-regulating genes in the renal tissue of patients with renal cell carcinoma. Nefrologiya = Nephrology (St. Petersburg), 2017, no. 21 (1), pp. 80-86. (In Russ.)
4. Pak D.D., Usov F.N., Fetisova E.Yu., Volchenko A.A., Efanov V.V. Current treatment options for breast carcinoma in situ. Onkologiya = Herzen Journal of Oncology, 2013, no. 4, pp. 34-39. (In Russ.)
5. Przedetskiy Yu.V., Vodolazhskiy D.I., Shatova Yu.S., Komova E.A., Dvadnenko K.V. In the RCA mutation in patients with clinical signs of hereditary breast cancer in the Southern Federal District. Zlokachestvennye opukholi = Malignant Tumors, 2015, Vol. 16, no. 4-2, pp. 196-197. (In Russ.)
6. Stenina M.B., Frolova M.A. Breast cancer: the most important scientific events and conclusions of recent years. Prakticheskaya onkologiya = Practical Oncology, 2011, no. 12 (1), pp. 6-11. (In Russ.)
7. Ahmad A. Pathways to breast cancer recurrence. ISRN Oncol., 2013, pp. 1-16.
8. Aoki M., Ueda S., Nishikawa H., Kitano S., Hirayama M., Ikeda H., Toyoda H., Tanaka K., Kanai M., Takabayashi A., Imai H., Shiraishi T., Sato E., Wada H., Nakayama E., Takei Y., Katayama N., Shiku H., Kageyama S. Antibody responses against NY-ESO-1 and HER2 antigens in patients vaccinated with combinations of cholesteryl pullulan (CHP)-NY-ESO-1 and CHPHER2 with OK-432. Vaccine, 2009, no. 49, pp. 6854-6861.
9. Bandic D., Juretic A., Sarcevic B., Separovic V., Kujundzic-Tiljak M., Hudolin T., Spagnoli G.C., Covic D., Samija M. Expression and possible prognostic role of MAGE-A4, NY-ESO-1, and HER-2 antigens in women with relapsing invasive ductal breast cancer: retrospective immunohistochemical study. Croat. Med. J., 2006, no. 1, pp. 32-41.
10. Chomczynski P, Sacchi N.The single-step method of RNA isolation by acid guanidinium thiocyanate-phenol-chloroform extraction: twenty-something years on. Nature Protocols, 2006, no. 2, pp. 581-585.
11. Curigliano G., Locatelli M., Fumagalli L., Goldhirsch A. Immunizing against breast cancer: a new swing for an old sword. Breast, 2009, no. 18, pp. 951-954.
12. Grigoriadis A., Caballero O.L., Hoek K.S., da Silva L., Chen Y.T., Shin S.J., Jungbluth A.A., Miller L.D., Clouston D., Cebon J., Old L.J., Lakhani S.R., Simpson A.J., Neville A.M. CT-X antigen expression in human breast cancer. Proc. Nat. Acad. Sci. USA, 2009, no. 32, pp. 13493-113498.
13. Hamai A., Duperrier-Amouriaux K., Pignon P., Raimbaud I., Memeo L., Colarossi C., Canzonieri V., Perin T., Classe J.M., Campone M., Jezequel P., Campion L., Ayyoub M., Valmori D. Antibody responses to NY-ESO-1 in primary breast cancer identify a subtype target for immunotherapy. PLoS ONE, 2011, no. 6, e21129. doi: 10.1371/journal.pone.0021129.
14. Kavalar R., Sarcevic B., Spagnoli G.C., Separovic V., Samija M., Terracciano L., Heberer M., Juretic A. Expression of MAGE tumour-associated antigens is inversely correlated with tumour differentiation in invasive ductal breast cancers: an immunohistochemical study. Virchows Arch., 2001, Vol. 439, no. 2, pp. 127-131.
15. Kruger S., Ola V., Feller A.C., Fischer D., Friedrich M. Expression of cancer-testis antigen CT7 (MAGE-C1) in breast cancer: an immunohistochemical study with emphasis on prognostic utility. Pathol. Oncol. Res., 2007, no. 2, pp. 91-96.
16. Matkovic B., Juretic A., Spagnoli G.C., Separovic V., Gamulin M., Separovic R., Saric N., Basic-Koretic M., Novosel I., Kruslin B. Expression of MAGE-A and NY-ESO-1 cancer/testis antigens in medullary breast cancer: retrospective immunohistochemical study. Croat. Med. J., 2011, no. 2, pp. 171-177.
17. Schmittgen T.D., Livak K.J. Analyzing real-time PCR data by the comparative CT method. Nature Protocols, 2008, no. 3, pp. 1101-1108.
18. Sugita Y., Wada H., Fujita S., Nakata T., Sato S., Noguchi Y., Jungbluth A.A., Yamaguchi M., Chen Y.T., Stockert E., Gnjatic S., Williamson B., Scanlan M.J., Ono T., Sakita I., Yasui M., Miyoshi Y., Tamaki Y., Matsuura N., Noguchi S., Old L.J., Nakayama E., Monden M. NY-ESO-1 expression and immunogenicity in malignant and benign breast tumors. Cancer Research, 2004, no. 6, pp. 2199-2204.
19. Theurillat J.P., Ingold F., Frei C., Zippelius A., Varga Z., Seifert B., Chen Y.T., Jager D., Knuth A., Moch H. NY-ESO-1 protein expression in primary breast carcinoma and metastases: correlation with CD8+ T-cell and CD79a+ plasmacytic/B-cell infiltration. Int. J. Cancer, 2007, no. 11, pp. 2411-2417.
Review
For citations:
Vodolazhskiy D.I., Kutilin D.S., Mogushkova Kh.A., Kit O.I. TRANSCRIPTIONAL PROFILE OF CANCER-TESTICULAR ANTIGENS IN PATIENTS WITH BREAST CANCER. Medical Immunology (Russia). 2018;20(3):383-390. (In Russ.) https://doi.org/10.15789/1563-0625-2018-3-383-390
Views:
896
Email this article 